ClinicalTrials.gg
TerminatedNCT04949191Updated Sep 19, 2024Results posted

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

A Phase 2 interventional study of Pemigatinib and Retifanlimab in Advanced Malignancies, sponsored by Incyte Corporation. Terminated at 10 sites in 4 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
A business decision due to availability of commercial drug and other options for accessing study drug treatment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.

Read the detailed description

A Phase 2 Open-Label, Multicenter, Rollover Study to evaluate the long term safety and tolerability of Pemigatinib and to provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

02

Conditions studied

  • Advanced Malignancies

Keywords

  • pemigatinib
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently enrolled and receiving treatment in an Incyte-sponsored clinical study (parent protocol) of pemigatinib as monotherapy or combination therapy.
  • Currently benefiting from and tolerating treatment with pemigatinib, as determined by the investigator.
  • Demonstrated compliance, as assessed by the investigator, with the parent protocol requirements.
  • Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures.
  • Currently have no evidence of progressive disease, as determined by the investigator, following treatment with pemigatinib as monotherapy or combination therapy.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Able to access pemigatinib commercially or outside of a clinical trial.
  • Permanently discontinued from the parent protocol for any reason.
  • No longer meet the inclusion/exclusion criteria from the parent protocol if still receiving treatment.
  • Women who are pregnant or breastfeeding or participants expecting to conceive or father children within the projected duration of the study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Study Treatment 1: Pemigatinib (INCB054828)

    Pemigatinib will be taken orally once daily

    Drug: Pemigatinib

  • Experimental
    Study Treatment 2: Pemigatininb+ Retifanlimab

    Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and retifanlimab will be administered once every 4 weeks

    Drug: Pemigatinib · Drug: Retifanlimab

  • Experimental
    Study Treatment 3: Pemigatininb + Pembrolizumab

    Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and pembroluzimab as per dosage instructions.

    Drug: Pemigatinib · Drug: Pembrolizumab

Interventions

  • Pemigatinib tablets taken by mouth once daily as per protocol

    Also known as: INCB054828

  • Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)

    Also known as: INCMGA0012

  • Commercially labeled products

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. TEAEs were defined as AEs either reported for the first time or the worsening of pre-existing events after the first dose of study drug and until 30 days after the last dose of study drug.

    Time frame: up to at least 30 days after the last dose of study treatment or until toxicities resolve, return to baseline, or are deemed irreversible, whichever was longer (up to 1010 days)

07

Results

Posted Sep 19, 2024

Participant flow

Participants who were actively receiving treatment with pemigatinib (monotherapy or in combination with pembrolizumab) under a parent protocol, were receiving clinical benefit in those trials, and who did not have access to pemigatinib (as monotherapy or as combination therapy) outside of a clinical trial were enrolled.

Participant flow — Overall Study
MilestonePemigatinib 6 mg MonotherapyPemigatinib 9 mg MonotherapyPemigatinib 13.5 mg MonotherapyPemigatinib Combination
Started2521
Completed1310
Not completed1211
Withdrew: Non-compliance with study drug1000
Withdrew: Progressive disease0100
Withdrew: Transitioned to commercial pemigatinib0100
Withdrew: Sponsor terminated study0011

Outcome measures

PrimaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. TEAEs were defined as AEs either reported for the first time or the worsening of pre-existing events after the first dose of study drug and until 30 days after the last dose of study drug.

Time frame:
up to at least 30 days after the last dose of study treatment or until toxicities resolve, return to baseline, or are deemed irreversible, whichever was longer (up to 1010 days)
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsPemigatinib 6 mg MonotherapyPemigatinib 9 mg MonotherapyPemigatinib 13.5 mg MonotherapyPemigatinib Combination
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)1511

Adverse events

Collected over up to 1010 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemigatinib 6 mg Monotherapy0/2 (0%)1/2 (50%)1/2 (50%)
Pemigatinib 9 mg Monotherapy0/5 (0%)2/5 (40%)5/5 (100%)
Pemigatinib 13.5 mg Monotherapy0/2 (0%)0/2 (0%)1/2 (50%)
Pemigatinib Combination0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventPemigatinib 6 mg MonotherapyPemigatinib 9 mg MonotherapyPemigatinib 13.5 mg MonotherapyPemigatinib Combination
Cardiac failureCardiac disorders1/20/50/20/1
Acute kidney injuryRenal and urinary disorders0/21/50/20/1
SeizureNervous system disorders0/21/50/20/1
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPemigatinib 6 mg MonotherapyPemigatinib 9 mg MonotherapyPemigatinib 13.5 mg MonotherapyPemigatinib Combination
ConstipationGastrointestinal disorders0/21/50/21/1
HaematuriaRenal and urinary disorders0/20/50/21/1
Joint swellingMusculoskeletal and connective tissue disorders0/20/50/21/1
StomatitisGastrointestinal disorders1/24/50/21/1
HypomagnesaemiaMetabolism and nutrition disorders0/20/50/21/1
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders1/24/50/20/1
Blood creatinine increasedInvestigations1/20/50/20/1
Drug hypersensitivityImmune system disorders0/20/51/20/1
Multiple allergiesImmune system disorders0/20/51/20/1
Muscular weaknessMusculoskeletal and connective tissue disorders0/20/51/20/1

Baseline characteristics

The 6 mg (n=2) and 13.5 mg (n=2) monotherapy groups have been combined into a single arm retain participant privacy and reduce the risk of participant re-identification.

Age, Continuous
Age, Continuous(years)Pemigatinib 6 mg and 13.5 mg MonotherapyPemigatinib 9 mg MonotherapyPemigatinib CombinationTotal
Mean64.5 ± 17.2061.2 ± 6.30NA ± NANA ± NA
Sex: Female, Male
Sex: Female, Male(Participants)Pemigatinib 6 mg and 13.5 mg MonotherapyPemigatinib 9 mg MonotherapyPemigatinib CombinationTotal
Female22NANA
Male23NANA
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pemigatinib 6 mg and 13.5 mg MonotherapyPemigatinib 9 mg MonotherapyPemigatinib CombinationTotal
Hispanic or Latino00NANA
Not Hispanic or Latino45NANA
Unknown or Not Reported00NANA
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pemigatinib 6 mg and 13.5 mg MonotherapyPemigatinib 9 mg MonotherapyPemigatinib CombinationTotal
White/Caucasian24NANA
Asian11NANA
Black/African-American10NANA
08

Study locations

10 sites
  • John Wayne Cancer Institute
    Santa Monica, California 90404, United States
  • Oncology Specialists of Charlotte
    Charlotte, North Carolina 28207, United States
  • Md Anderson Cancer Center
    Houston, Texas 77030, United States
  • South Texas Accelerated Research Therapeutics
    San Antonio, Texas 78229, United States
  • Virginia Cancer Specialists, Pc
    Fairfax, Virginia 22031, United States
  • The Finsen Centre National Hospital
    Copenhagen, 02100, Denmark
  • Fondazione Irccs Istituto Nazionale Dei Tumori
    Milan, 20133, Italy
  • Istituto Nazionale Tumori Regina Elena Irccs
    Rome, 00144, Italy
  • Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte
    Siena, 53100, Italy
  • Kanagawa Cancer Center
    Yokohama-Shi, 241-8515, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Apr 2024, 33 months.

Results were first posted in Sep 2024, 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2021
First posted
Jul 2, 2021
StartActual
Jul 8, 2021
Primary completionActual
Apr 11, 2024
CompletionActual
Apr 11, 2024
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04949191
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jul 2, 2021
Start date
Jul 8, 2021
Primary completion
Apr 11, 2024
Completion
Apr 11, 2024
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Peter Langmuir
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion